Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.47 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962937 | 0.85 | KMT2A (0.51) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL21962922 | 0.84 | KMT2A (0.57) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL7332197 | 0.84 | KMT2A (0.50) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL7335528 | 0.84 | KMT2A (0.50) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL7415092 | 0.82 | KMT2A (0.52) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL25829681 | 0.82 | KMT2A (0.49) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL7269972 | 0.81 | POLB (0.48) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL25829682 | 0.79 | KMT2A (0.46) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL25829683 | 0.79 | KMT2A (0.52) | MEN1KMT2ACA12CA2CA7 | |
| SCHEMBL3596338 | 0.78 | ALDH1A1 (0.57) | MEN1KMT2APOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5523289-A | RENIN INHIBITOR | ABBOTT LABORATORIES (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0456185-B1 | Renin inhibitors | ABBOTT LAB (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5344990-A | Process for the preparation of a renin inhibiting compound | ABBOTT LABORATORIES (US) | 1994-09-06 | — | — | US | disclosed |
| US-5332742-A | Ocular hypotensive | ABBOTT LABORATORIES (US) | 1994-07-26 | — | — | US | disclosed |
| US-5310740-A | Congestive heart failure, hypotensive agents, antiglaucoma agents; side effect reduction | ABBOTT LABORATORIES (US) | 1994-05-10 | — | — | US | disclosed |
| US-5284849-A | Treating hypertension and congestive heart failure | ABBOTT LABORATORIES (US) | 1994-02-08 | — | — | US | disclosed |
| US-5275950-A | Process for the preparation of a renin inhibiting compound | ABBOTT LABORATORIES (US) | 1994-01-04 | — | — | US | disclosed |
| US-5276031-A | Method for treating renal disease | ABBOTT LABORATORIES (US) | 1994-01-04 | — | — | US | disclosed |
| US-5258362-A | Enzyme inhibitors, amides with oxetane ring | ABBOTT LABORATORIES (US) | 1993-11-02 | — | — | US | disclosed |
| WO-1993002667-A1 | PHARMACEUTICAL COMPOSITION | ABBOTT LABORATORIES (US) | 1993-02-18 | — | — | WO | disclosed |
| US-5182266-A | Method for treating renal disease | ABBOTT LABORATORIES (US) | 1993-01-26 | — | — | US | disclosed |
| US-5178877-A | Cardiovascular disorders | ABBOTT LABORATORIES (US) | 1993-01-12 | — | — | US | disclosed |
| US-5122514-A | Administering renin inhibitor | ABBOTT LABORATORIES (US) | 1992-06-16 | — | — | US | disclosed |
| EP-0456185-A2 | Renin inhibitors | ABBOTT LABORATORIES (US) | 1991-11-13 | — | — | EP | disclosed |
| WO-1991016031-A1 | PSORIASIS TREATMENT | ABBOTT LABORATORIES (US) | 1991-10-31 | — | — | WO | disclosed |
| EP-0440102-A1 | Method for treating renal disease | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| EP-0416393-A1 | Peptidyl difluorodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |